Life science and clinical research company Thermo Fisher Scientific Inc (NYSE:TMO) announced on Thursday that it has opened a Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco to accelerate structural insights and drug development.

The facility offers pharmaceutical and biotechnology innovators hands-on access to advanced cryo-EM technologies designed to lower adoption barriers and speed the development of life-saving therapies.

Cryo-EM supports structure-guided drug discovery, enabling more than twice the clinical success rate in half the preclinical time and at half the cost compared with industry standards. The South San Francisco facility builds on the UK Pharmaceutical Cryo-EM Consortium in Cambridge, established in 2016, marking a decade of collaboration with five leading pharmaceutical companies.

Modelled after the UK consortium, the US CDDC will include founding customer members to extend this collaborative framework to North America. Located in the Oyster Point area, it integrates state-of-the-art instrumentation with a collaborative scientific environment.